Literature DB >> 22393169

Alterations in brain transition metals in Huntington disease: an evolving and intricate story.

H Diana Rosas1, Y Iris Chen, Gheorghe Doros, David H Salat, Nan-kuei Chen, Ken K Kwong, Ashley Bush, Jonathan Fox, Steven M Hersch.   

Abstract

BACKGROUND: Aberrant accumulation of transition metals in the brain may have an early and important role in the pathogenesis of several neurodegenerative disorders, including Huntington disease (HD).
OBJECTIVE: To comprehensively evaluate and validate the distribution of metal deposition in the brain using advanced magnetic resonance imaging methods from the premanifest through symptomatic stages of HD.
DESIGN: Observational study.
SETTING: University imaging center. PARTICIPANTS: Twenty-eight HD expanded gene carriers, 34 patients with symptomatic HD, and 56 age- and sex-matched healthy control subjects were included in the study.
INTERVENTIONS: Participants underwent magnetic resonance imaging for the quantification of the phase evolution of susceptibility-weighted images. MAIN OUTCOME MEASURES: To verify the identity of the metals responsible for the changes in the phase evolution of the susceptibility signal in the brain and to assess correlations with systemic levels. Inductively coupled plasma mass spectrometry was used to measure transition metal concentrations in postmortem brains.
RESULTS: In the basal ganglia, progressive increases in the phase evolution were found in HD, beginning in premanifest individuals who were far from expected onset and increasing with proximity to expected onset and thereafter. Increases in the cerebral cortex were regionally selective and present only in symptomatic HD. Increases were verified by excessive deposition of brain iron, but a complex alteration in other transition metals was found.
CONCLUSION: An important and early role of altered metal homeostasis is suggested in the pathogenesis of HD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22393169      PMCID: PMC3652228          DOI: 10.1001/archneurol.2011.2945

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  27 in total

1.  Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex.

Authors:  B Fischl; A Liu; A M Dale
Journal:  IEEE Trans Med Imaging       Date:  2001-01       Impact factor: 10.048

2.  Quantitative neuropathological changes in presymptomatic Huntington's disease.

Authors:  E Gómez-Tortosa; M E MacDonald; J C Friend; S A Taylor; L J Weiler; L A Cupples; J Srinidhi; J F Gusella; E D Bird; J P Vonsattel; R H Myers
Journal:  Ann Neurol       Date:  2001-01       Impact factor: 10.422

3.  Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease.

Authors:  M B Bogdanov; O A Andreassen; A Dedeoglu; R J Ferrante; M F Beal
Journal:  J Neurochem       Date:  2001-12       Impact factor: 5.372

4.  Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.

Authors:  Jonathan H Fox; Teal Connor; Megan Stiles; Jibrin Kama; Zhen Lu; Kathryn Dorsey; Gregory Lieberman; Gregory Liebermann; Ellen Sapp; Robert A Cherny; Mary Banks; Irene Volitakis; Marian DiFiglia; Oksana Berezovska; Ashley I Bush; Steven M Hersch
Journal:  J Biol Chem       Date:  2011-03-30       Impact factor: 5.157

5.  Rate of functional decline in Huntington's disease. Huntington Study Group.

Authors:  K Marder; H Zhao; R H Myers; M Cudkowicz; E Kayson; K Kieburtz; C Orme; J Paulsen; J B Penney; E Siemers; I Shoulson
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

Review 6.  Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2004-03       Impact factor: 5.691

7.  Thinning of the cerebral cortex in aging.

Authors:  David H Salat; Randy L Buckner; Abraham Z Snyder; Douglas N Greve; Rahul S R Desikan; Evelina Busa; John C Morris; Anders M Dale; Bruce Fischl
Journal:  Cereb Cortex       Date:  2004-03-28       Impact factor: 5.357

Review 8.  Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group.

Authors:  D T Dexter; P Jenner; A H Schapira; C D Marsden
Journal:  Ann Neurol       Date:  1992       Impact factor: 10.422

9.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

10.  Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus.

Authors:  R H Myers; J P Vonsattel; P A Paskevich; D K Kiely; T J Stevens; L A Cupples; E P Richardson; E D Bird
Journal:  J Neuropathol Exp Neurol       Date:  1991-11       Impact factor: 3.685

View more
  51 in total

1.  Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease.

Authors:  J M G van Bergen; J Hua; P G Unschuld; I A L Lim; C K Jones; R L Margolis; C A Ross; P C M van Zijl; X Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-17       Impact factor: 3.825

2.  Comparison of histological techniques to visualize iron in paraffin-embedded brain tissue of patients with Alzheimer's disease.

Authors:  Sara van Duijn; Rob J A Nabuurs; Sjoerd G van Duinen; Remco Natté
Journal:  J Histochem Cytochem       Date:  2013-07-25       Impact factor: 2.479

Review 3.  Mitochondrial metals as a potential therapeutic target in neurodegeneration.

Authors:  A Grubman; A R White; J R Liddell
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

4.  Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically.

Authors:  Sonal Agrawal; Julia Fox; Baskaran Thyagarajan; Jonathan H Fox
Journal:  Free Radic Biol Med       Date:  2018-04-04       Impact factor: 7.376

5.  Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate.

Authors:  Giovanna Rassu; Elena Soddu; Massimo Cossu; Antonio Brundu; Guido Cerri; Nicola Marchetti; Luca Ferraro; Raymond F Regan; Paolo Giunchedi; Elisabetta Gavini; Alessandro Dalpiaz
Journal:  J Control Release       Date:  2015-01-22       Impact factor: 9.776

6.  Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model.

Authors:  Terry Jo V Bichell; Michal Wegrzynowicz; K Grace Tipps; Emma M Bradley; Michael A Uhouse; Miles Bryan; Kyle Horning; Nicole Fisher; Karrie Dudek; Timothy Halbesma; Preethi Umashanker; Andrew D Stubbs; Hunter K Holt; Gunnar F Kwakye; Andrew M Tidball; Roger J Colbran; Michael Aschner; M Diana Neely; Alba Di Pardo; Vittorio Maglione; Alexander Osmand; Aaron B Bowman
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-02-16       Impact factor: 5.187

7.  A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.

Authors:  Andrew M Tidball; Miles R Bryan; Michael A Uhouse; Kevin K Kumar; Asad A Aboud; Jack E Feist; Kevin C Ess; M Diana Neely; Michael Aschner; Aaron B Bowman
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

8.  Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.

Authors:  Lin Chen; Jun Hua; Christopher A Ross; Shuhui Cai; Peter C M van Zijl; Xu Li
Journal:  J Neurosci Res       Date:  2018-11-29       Impact factor: 4.164

9.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

Review 10.  The Emerging Roles of Ferroptosis in Huntington's Disease.

Authors:  Yajing Mi; Xingchun Gao; Hao Xu; Yuanyuan Cui; Yuelin Zhang; Xingchun Gou
Journal:  Neuromolecular Med       Date:  2019-01-02       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.